NJ State Employees Deferred Compensation Plan’s Kindred Biosciences, Inc. KIN Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-32,000	Closed	-$293K	–	515
2021 Q2	$293K	Hold	32,000	–	–	0.04%	423
2021 Q1	$159K	Hold	32,000	–	–	0.02%	494
2020 Q4	$138K	Hold	32,000	–	–	0.02%	475
2020 Q3	$137K	Hold	32,000	–	–	0.02%	442
2020 Q2	$144K	Hold	32,000	–	–	0.03%	441
2020 Q1	$128K	Hold	32,000	–	–	0.03%	416
2019 Q4	$271K	Hold	32,000	–	–	0.05%	429
2019 Q3	$219K	Hold	32,000	–	–	0.04%	459
2019 Q2	$267K	Hold	32,000	–	–	0.05%	462
2019 Q1	$293K	Buy	32,000 +9,000	+39%	+$91.4K	0.05%	437
2018 Q4	$252K	Hold	23,000	–	–	0.05%	414
2018 Q3	$321K	Sell	23,000 -17,000	-43%	-$230K	0.05%	421
2018 Q2	$426K	Sell	40,000 -10,000	-20%	-$97.5K	0.08%	358
2018 Q1	$433K	Hold	50,000	–	–	0.08%	338
2017 Q4	$473K	Buy	+50,000	New	+$391K	0.08%	341

Other funds holding KIN

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's KIN Position: Q3 2021 in Review

NJ State Employees Deferred Compensation Plan sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 32,000 shares — an estimated $293K sold.

NJ State Employees Deferred Compensation Plan first reported a position in KIN in Q4 2017 and held it in 15 quarters. The position peaked at $473K in Q4 2017. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.

NJ State Employees Deferred Compensation Plan reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 32,000 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $293K.
NJ State Employees Deferred Compensation Plan first reported a position in Kindred Biosciences, Inc. in Q4 2017 and held it in 15 quarters.
NJ State Employees Deferred Compensation Plan's Kindred Biosciences, Inc. position peaked at $473K in Q4 2017.
1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q3 2021, filed 26 Oct 2021.